• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对免疫记录的探索性分析表明，近期接种过非 COVID-19 疫苗的个体中 SARS-CoV-2 感染率降低。

Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.

机构信息

Nference, Inc., One Main Street, Suite 400, East Arcade, Cambridge, MA, 02142, USA.

Mayo Clinic, Rochester, MN, USA.

出版信息

Sci Rep. 2021 Feb 26;11(1):4741. doi: 10.1038/s41598-021-83641-y.

DOI:10.1038/s41598-021-83641-y
PMID:33637783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910541/
Abstract

Clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Haemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), Varicella, pneumococcal conjugate (PCV13), Geriatric Flu, and hepatitis A/hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI (0.32, 0.64), p-value: 6.9e-05). Overall, this study identifies existing approved vaccines which can be promising candidates for pre-clinical research and Randomized Clinical Trials towards combating COVID-19.

摘要

临床研究正在进行中，以评估现有的疫苗是否可以通过训练有素的免疫来提供针对 SARS-CoV-2 感染的保护。在这项探索性研究中，我们分析了 137037 名接受 SARS-CoV-2 PCR 检测的个体的免疫记录。我们发现，过去 1、2 和 5 年内接种的脊髓灰质炎、流感嗜血杆菌 b 型（HIB）、麻疹-腮腺炎-风疹（MMR）、水痘、肺炎球菌结合疫苗（PCV13）、老年流感和甲型肝炎/乙型肝炎（HepA-HepB）疫苗与 SARS-CoV-2 感染率降低有关，即使在调整了地理 SARS-CoV-2 发病率和检测率、人口统计学、合并症和其他疫苗接种数量后也是如此。此外，年龄、种族/民族和血型分层分析显示，过去 5 年内接种过 PCV13 疫苗的黑人个体 SARS-CoV-2 率显著降低，相对风险为 0.45（n：653，95%CI（0.32，0.64），p 值：6.9e-05）。总体而言，这项研究确定了现有的批准疫苗，它们可能是对抗 COVID-19 的临床前研究和随机临床试验的有前途的候选疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/c1b8c28c7db1/41598_2021_83641_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/8108d5f5aa94/41598_2021_83641_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/58bdc7c99364/41598_2021_83641_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/8d0aeeefe69c/41598_2021_83641_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/0e41e1fe7226/41598_2021_83641_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/5960845f5dd8/41598_2021_83641_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/c1b8c28c7db1/41598_2021_83641_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/8108d5f5aa94/41598_2021_83641_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/58bdc7c99364/41598_2021_83641_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/8d0aeeefe69c/41598_2021_83641_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/0e41e1fe7226/41598_2021_83641_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/5960845f5dd8/41598_2021_83641_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe7/7910541/c1b8c28c7db1/41598_2021_83641_Fig6_HTML.jpg

相似文献

1
Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.对免疫记录的探索性分析表明，近期接种过非 COVID-19 疫苗的个体中 SARS-CoV-2 感染率降低。
Sci Rep. 2021 Feb 26;11(1):4741. doi: 10.1038/s41598-021-83641-y.
2
National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.2014 年美国 19-35 月龄儿童全国、州和部分地区疫苗接种覆盖率。
MMWR Morb Mortal Wkly Rep. 2015 Aug 28;64(33):889-96. doi: 10.15585/mmwr.mm6433a1.
3
Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.与未接种七价肺炎球菌结合疫苗时接种的麻疹-腮腺炎-风疹疫苗、水痘疫苗和b型流感嗜血杆菌疫苗相比，同时接种第四剂七价肺炎球菌结合疫苗时这些疫苗的免疫原性和安全性。
Pediatr Infect Dis J. 2006 Apr;25(4):306-11. doi: 10.1097/01.inf.0000207409.92198.6f.
4
Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.麻疹、腮腺炎、风疹和水痘疫苗与b型流感嗜血杆菌结合疫苗/乙型肝炎疫苗联合接种以及与白喉-破伤风-无细胞百日咳联合疫苗接种时的安全性和免疫原性。
Pediatr Infect Dis J. 2006 Apr;25(4):287-92. doi: 10.1097/01.inf.0000207857.10947.1f.
5
Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'.麻疹、腮腺炎和风疹与白喉-破伤风-无细胞百日咳-灭活脊髓灰质炎-乙型流感嗜血杆菌疫苗相比，作为最新的疫苗，与早期“儿童哮喘”的风险。
Int J Epidemiol. 2019 Dec 1;48(6):2026-2038. doi: 10.1093/ije/dyz062.
6
Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.麻疹、腮腺炎和风疹活疫苗与非目标感染住院风险。
JAMA. 2014 Feb 26;311(8):826-35. doi: 10.1001/jama.2014.470.
7
Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.以色列幼儿常规儿童疫苗接种的适龄与最新覆盖情况。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2102-2110. doi: 10.1080/21645515.2017.1341028. Epub 2017 Jul 11.
8
Timeliness and completeness of routine childhood vaccinations in young children residing in a district with recurrent vaccine-preventable disease outbreaks, Jerusalem, Israel.以色列耶路撒冷，在一个经常发生疫苗可预防疾病爆发的地区，居住的幼儿常规儿童疫苗接种的及时性和完整性。
Euro Surveill. 2019 Feb;24(6). doi: 10.2807/1560-7917.ES.2019.24.6.1800004.
9
Simultaneous vaccination of Chinese applicants for a United States immigrant visa.同时为申请美国移民签证的中国申请人接种疫苗。
Travel Med Infect Dis. 2008 May;6(3):130-6. doi: 10.1016/j.tmaid.2008.03.004.
10
Vaccination Coverage Among Children Aged 19-35 Months - United States, 2015.19-35 月龄儿童疫苗接种覆盖率 - 美国，2015 年。
MMWR Morb Mortal Wkly Rep. 2016 Oct 7;65(39):1065-1071. doi: 10.15585/mmwr.mm6539a4.

引用本文的文献

1
The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria-Tetanus-Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity.印度尼西亚儿童接种白喉-破伤风-百日咳疫苗和新冠病毒疫苗后对新冠病毒适应性免疫反应的改善：探索异源免疫的作用
Vaccines (Basel). 2024 Sep 9;12(9):1032. doi: 10.3390/vaccines12091032.
2
Evaluation of the Effect of Influenza Vaccine on the Development of Symptoms in SARS-CoV-2 Infection and Outcome in Patients Hospitalized due to COVID-19.评估流感疫苗对SARS-CoV-2感染症状发展及因COVID-19住院患者预后的影响。
Vaccines (Basel). 2024 Jul 12;12(7):765. doi: 10.3390/vaccines12070765.
3

本文引用的文献

1
Collider bias undermines our understanding of COVID-19 disease risk and severity.撞击器偏差破坏了我们对 COVID-19 疾病风险和严重程度的理解。
Nat Commun. 2020 Nov 12;11(1):5749. doi: 10.1038/s41467-020-19478-2.
2
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的安全性和免疫原性：一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
3
BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).
Non-specific protection against severe COVID-19 associated to typhoid fever and DTP vaccination.
针对与伤寒热和百白破疫苗接种相关的重症新冠病毒病的非特异性保护作用。
Heliyon. 2024 Apr 23;10(9):e29935. doi: 10.1016/j.heliyon.2024.e29935. eCollection 2024 May 15.
4
Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.疫苗可诱导稳态免疫，产生多种次要益处。
Vaccines (Basel). 2024 Apr 9;12(4):396. doi: 10.3390/vaccines12040396.
5
Specific and Nonspecific Effects of Influenza Vaccines.流感疫苗的特异性和非特异性作用
Vaccines (Basel). 2024 Apr 5;12(4):384. doi: 10.3390/vaccines12040384.
6
Associations of infections and vaccines with Alzheimer's disease point to a role of compromised immunity rather than specific pathogen in AD.感染和疫苗与阿尔茨海默病的关联表明，在阿尔茨海默病中，免疫功能受损而非特定病原体发挥了作用。
Exp Gerontol. 2024 Jun 1;190:112411. doi: 10.1016/j.exger.2024.112411. Epub 2024 Apr 2.
7
Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination.灭活脊髓灰质炎病毒疫苗加强针可降低口服脊髓灰质炎疫苗初免个体出现新冠病毒感染相关结果的可能性。
Vaccines (Basel). 2024 Feb 20;12(3):219. doi: 10.3390/vaccines12030219.
8
Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID-19: A systematic review and meta-analysis.接种流感疫苗可降低呼吸道 COVID-19 的感染率，而非住院率或死亡率：系统评价和荟萃分析。
J Med Virol. 2024 Jan;96(1):e29343. doi: 10.1002/jmv.29343.
9
Acceptance of COVID-19 vaccine booster dose among the people of Bangladesh: A cross-sectional study.孟加拉国人群对新冠病毒疫苗加强针的接受情况：一项横断面研究。
Heliyon. 2023 Nov 11;9(11):e22215. doi: 10.1016/j.heliyon.2023.e22215. eCollection 2023 Nov.
10
Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study.流感免疫对 COVID-19 住院老年患者死亡率的影响：一项回顾性队列研究。
Clin Exp Med. 2023 Dec;23(8):4955-4965. doi: 10.1007/s10238-023-01203-0. Epub 2023 Oct 31.
BCG 疫苗可预防严重的 2019 年冠状病毒病（COVID-19）。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726. doi: 10.1073/pnas.2008410117. Epub 2020 Jul 9.
4
Can existing live vaccines prevent COVID-19?现有的活疫苗能预防新冠病毒病吗？
Science. 2020 Jun 12;368(6496):1187-1188. doi: 10.1126/science.abc4262.
5
Considering BCG vaccination to reduce the impact of COVID-19.考虑接种卡介苗以减轻新型冠状病毒肺炎的影响。
Lancet. 2020 May 16;395(10236):1545-1546. doi: 10.1016/S0140-6736(20)31025-4. Epub 2020 Apr 30.
6
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
7
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
8
Defining trained immunity and its role in health and disease.定义训练免疫及其在健康和疾病中的作用。
Nat Rev Immunol. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6. Epub 2020 Mar 4.
9
Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations.基于训练免疫的疫苗：广谱抗感染配方开发的新模式。
Front Immunol. 2018 Dec 17;9:2936. doi: 10.3389/fimmu.2018.02936. eCollection 2018.
10
Risk in vaccine research and development quantified.疫苗研发风险量化。
PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20.